TLDR
- Wellgistics unveils PharmacyChain™ blockchain while shares drop sharply.
- WGRX falls 27% as bold blockchain strategy enters pharma spotlight.
- Wellgistics partners with DataVault AI to launch smart prescription tech.
- WGRX pivots to blockchain, targets patient-first pharma future.
- New PharmacyChain™ vision fuels tech expansion, shakes up WGRX stock.
WGRX stock dropped over 27% today, closing at $0.8389, amid sharp volatility and limited upward recovery.
Wellgistics Health, Inc., WGRX
The steep decline followed the company’s announcement of its PharmacyChain blockchain initiative in partnership with DataVault AI. While the market reacted negatively, WGRX reaffirmed its focus on digital transformation through smart contracts and patient-centered distribution.
Blockchain Agreement Sets Foundation for New Market Expansion
WGRX signed a SAAS agreement with DataVault AI to develop its PharmacyChain blockchain platform. This platform will enable secure, real-time prescription routing, verification, and fulfillment using smart contracts tailored for the pharmaceutical supply chain. The company aims to finalize a profit-sharing agreement in Q4 2025 after identifying revenue streams.
The partnership intends to improve how prescriptions flow from manufacturers to patients, ensuring faster insurance processing and better fulfillment accuracy. WGRX expects this blockchain solution to give it a strategic edge in both existing and new markets. PharmacyChain™ will begin beta testing in early 2026 as development continues on core features.
The project also responds to growing demand for transparency, digital routing, and real-time pharmaceutical data. It integrates AI and blockchain to power smart contracts across Wellgistics’ technology infrastructure. By doing so, WGRX hopes to create a standardized system for smart prescription handling and analytics.
Strategic Technology Drive Aims to Redefine Drug Fulfillment
PharmacyChain will utilize blockchain to automate data flows between manufacturers, pharmacies, and physicians with security and traceability. WGRX believes this will enhance prescription accuracy while cutting delays in reimbursement and delivery. The system also creates transparency for all stakeholders involved in the drug distribution process.
DataVault AI will supply patented technology, including secure token-based data scoring and monetization to support system functionality. Their Web 3.0 platform will enable real-time data exchange, empowering pharmacists with the right data at the right time. WGRX positions this partnership as the backbone of its next growth stage.
Through this collaboration, the company intends to unlock new digital revenue streams within the $639 billion prescription drug market. PharmacyChain will also introduce utility tokens and digital twins of patient profiles, optimizing drug recommendations. WGRX believes these innovations will help build a personalized, data-driven pharmaceutical experience.
Vision Includes Biometrics and Direct-to-Patient Capabilities
PharmacyChain plans to include biometric and diagnostic data on a consented, opt-in basis for improved alignment with health outcomes. Patients and physicians will gain access to real-time insights that combine prescriptions with lifestyle and wellness recommendations. WGRX aims to bring AI and data science to everyday prescription use.
The company also sees opportunities to support direct-to-patient sales, enabling manufacturers to tailor messaging and offers through improved data visibility. This supports the broader vision of integrating pharmaceutical and wellness strategies through the use of blockchain and AI. WGRX believes combining wearables and diagnostics can power more effective patient engagement.
The new platform will also allow for more personalized and efficient drug dispensing, supported by real-time verification and fulfillment metrics. The goal is to build a closed-loop ecosystem that benefits all parties involved in drug delivery. WGRX continues to reshape its identity as a tech-forward pharmaceutical distributor.

